Claims

- 1. A viral expression vector comprising a nucleic
- 2 acid which comprises (1) a transcriptional start site; (2) a
- 3 promoter operably linked to the transcriptional start site;
- 4 and (3) an enhancer operably linked to the promoter, the
- 5 enhancer comprising the DNA sequence of SEQ ID NO:1 or the
- 6 RNA equivalent thereof.
- 1 2. The viral expression vector of claim 1, wherein
- 2 the vector is a retrovirus.
- 1 3. The viral expression vector of claim 1, wherein
- 2 the promoter drives transcription of a mRNA encoding a
- 3 polypeptide, the transcription beginning from the
- 4 transcriptional start site.
- 1 4. The viral expression vector of claim 3, wherein
- 2 the polypeptide is a growth hormone.
- 1 5. The viral expression vector of claim 1, wherein
- 2 the promoter is a tissue-specific promoter.
- 1 6. The viral expression vector of claim 5, wherein
- 2 the promoter is a \(\cdot \text{globin promoter.} \)
- 7. The viral expression vector of claim 1, wherein
- 2 the enhancer comprises SEQ ID NO:2 or the RNA equivalent
- 3 thereof.
- 1 8. The viral expression vector of claim 7, wherein
- 2 the enhancer comprises SEQ ID NO:3 or the RNA equivalent
- 3 thereof.

- 1 9. The viral expression vector of claim 1, wherein
- 2 the nucleic acid further comprises a transcriptional
- 3 termination signal that terminates transcription from the
- 4 transcriptional start site.
- 1 10. The viral expression vector of claim 9, wherein
- 2 the vector is a retrovirus.
- 1 11. The viral expression vector of claim 9, wherein
- 2 the promoter drives transcription of a mRNA encoding a
- 3 polypeptide, the transcription beginning from the
- 4 transcriptional start site.
- 1 12. The viral expression vector of claim 9, wherein
 - the transcriptional termination signal is a polyadenylation
 - 3 signal.

2

- 1 13. A transgenic animal whose somatic and germ line
- 2 cells contain at least one copy of a transgene comprising
- 3 (1) a transcriptional start site; (2) a promoter operably
 - linked to the transcriptional start site; and (3) an
- 5 enhancer operably linked to the promoter, the enhancer
- 6 comprising the nucleotide sequence of SEQ ID NO:1,
- 7 wherein the transgenic animal expresses a transcript
- 8 driven by the promoter, the level of expression in at least
- 9 one cell type of the animal being proportionally dependent
- on the copy number of the transgene.
 - 1 14. The transgenic animal of claim 13, wherein the
 - 2 animal is a rodent.

- 1 15. The transgenic animal of claim 14, wherein the 2 animal is a mouse.
- 1 16. The transgenic animal of claim 15, wherein the
- 2 somatic and germ line cells contain more than 5 copies of
- 3 the transgene.
- 1 17. The transgenic animal of claim 16, wherein the
- 2 somatic and germ line cells contain more than 15 copies of
- 3 the transgene.
- 1 18. The transgenic animal of claim 17, wherein the
- 2 promoter drives transcription of a mRNA encoding a
- 3 polypeptide, the transcription beginning from the
- 4 transcriptional start site.
- 1 19. The transgenic animal of claim 18, wherein the
- 2 polypeptide is a growth hormone.
- 1 20. The transgenic animal of claim 19, wherein the
- 2 promoter is a ζ -globin promoter, and the at least one cell
- 3 type is a erythroblast.
- 1 21. The transgenic animal of claim 20, wherein the
- 2 enhancer comprises SEQ ID NO:2.
- 1 22. The transgenic animal of claim 21, wherein the
- 2 enhancer comprises SEQ ID NO:3.